Benzinga · Sep 11, 2026
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
MN
NASDAQ · MNPR
Monopar Therapeutics Inc.
Healthcare · Biotechnology
$101.45
Down-$2.88 (-2.76%)
Updated Sep 17, 2026, 9:45 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 514.56M
- P/E ratio
- -0.16
- Dividend yield
- 0.00%
- 52-week range
- $50.07 – $124.82
- Volume
- 90.41K
- Avg. volume
- 123.73K
Price performance
MNPR price history
1M range · 0 trading sessions · Daily adjusted prices
MNPR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest MNPR news
The latest Smart Investors Daily articles mentioning MNPR.
Stock researchCompany · Overview
MNPR research
Overview
Company profile and research snapshot.
Company profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $107.43
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Barclays | Overweight | — |
| Aug 13, 2026 | Barclays | Overweight | — |
| Aug 13, 2026 | Cantor Fitzgerald | Neutral | — |
| Aug 12, 2026 | BTIG | Buy | — |
| Jul 22, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 19, 2026
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate
Benzinga · Aug 13, 2026
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
Benzinga · Aug 13, 2026
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
